{
    "clinical_study": {
        "@rank": "119181", 
        "arm_group": [
            {
                "arm_group_label": "Phase 1 Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1.  Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5."
            }, 
            {
                "arm_group_label": "Phase 1 Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1.  Anti-OX40 will be administered at 0.2 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5."
            }, 
            {
                "arm_group_label": "Phase 1 Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1.  Anti-OX40 will be administered at 0.4 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5."
            }, 
            {
                "arm_group_label": "Phase 2 Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1.  Anti-OX40 will be administered i.v. at the Phase 1 Maximum Tolerated Dose over 60 minutes only in the first week on Days 1, 3 and 5."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open label, two-phase study combining a dose escalation Phase 1 with a\n      proof-of-concept Phase 2 in patients with unresectable or metastatic melanoma, for whom\n      treatment with ipilimumab is indicated.\n\n      The purpose of the Phase 1 is to determine  the Anti-OX40 Maximum Tolerated Dose (MTD) and\n      the secondary objectives are anti-OX40 pharmacokinetics, biological activity and the tumor\n      response assessed by the Immune-related Response Criteria.\n\n      The purpose of  Phase 2 is to determine tumor response (by irRC) and the secondary\n      objectives are anti-OX40 pharmacokinetics, biological activity and Safety/Tolerability."
        }, 
        "brief_title": "Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with unresectable or metastatic melanoma, for whom treatment with Ipilimumab\n             is indicated\n\n          -  Radiologically measurable disease by immune-related Response Criteria\n\n          -  ECOG performance status of 0-1.\n\n          -  Anticipated lifespan greater than 12 weeks.\n\n          -  At the time of day 1 of the study, patients must be at least 3 weeks since surgery\n\n          -  At the time of day 1 of the study, patients with brain metastases must be\n             asymptomatic and, at least 8 weeks without tumor progression after any whole brain\n             radiotherapy, at least 4 weeks since craniotomy and resection or stereotactic\n             radiosurgery, at least 3 weeks without new brain metastases as evidenced by MRI/CT\n\n          -  The following laboratory parameters must be within the ranges specified: Hemoglobin-\u2265\n             9 g/dL, WBC-\u2265 3.0 x 109/L, INR-\u2264 1.5, Total Bilirubin-\u2264 1.9 g/dL & AST/ALT-\u2264 3 x ULN\n\n          -  Have been informed of other treatment options.\n\n          -  At least 18 years. Able and willing to give valid written informed consent.\n\n        Exclusion Criteria:\n\n          -  Any contraindications for ipilimumab/Yervoy\u00ae.\n\n          -  Prior exposure to ipilimumab/Yervoy\u00ae\n\n          -  Prior exposure to Anti-OX40 or a mouse monoclonal antibody.\n\n          -  History of severe allergic reactions to any unknown allergens or anti-OX40 Autoimmune\n             disease except for autoimmune thyroiditis or vitiligo.\n\n          -  Unresolved immune related adverse events following prior biological therapy.\n\n          -  Metastatic disease to the central nervous system for which other therapeutic options,\n             including radiotherapy, may be available.\n\n          -  Known immunodeficiency or HIV, Hepatitis B or Hepatitis C positivity.\n\n          -  Other serious illnesses (e.g., serious infections requiring antibiotics).\n\n          -  Participation in any other clinical trial involving another investigational agent\n             within 4 weeks prior to day 1 of the study.\n\n          -  Mental impairment that may compromise the ability to give informed consent and comply\n             with the requirements of the study.\n\n          -  Lack of availability for immunological and clinical follow-up assessments.\n\n          -  Women who are breast feeding or pregnant as evidenced by positive serum pregnancy\n             test (minimum sensitivity 25 IU/L or equivalent units of HCG) done within 72 hours of\n             first dosing.\n\n          -  Women of childbearing potential not using a medically acceptable means of\n             contraception for the duration of the study.\n\n          -  Any condition that, in the clinical judgment of the treating physician, is likely to\n             prevent the patient from complying with any aspect of the protocol or that may put\n             the patient at unacceptable risk."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689870", 
            "org_study_id": "LUD2012-005"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Phase 1 Cohort 1", 
                    "Phase 1 Cohort 2", 
                    "Phase 1 Cohort 3", 
                    "Phase 2 Cohort 4"
                ], 
                "description": "Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5", 
                "intervention_name": "Anti-OX40", 
                "intervention_type": "Drug", 
                "other_name": "CD134 mab"
            }, 
            {
                "arm_group_label": [
                    "Phase 1 Cohort 1", 
                    "Phase 1 Cohort 2", 
                    "Phase 1 Cohort 3", 
                    "Phase 2 Cohort 4"
                ], 
                "description": "Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug", 
                "other_name": "YERVOY"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "OX40", 
            "Anti-OX40", 
            "Ipilimumab", 
            "Melanoma"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma", 
        "overall_official": [
            {
                "affiliation": "Memorial Sloan-Kettering Cancer Center", 
                "last_name": "Jedd Wolchok, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Providence Health & Services", 
                "last_name": "Brendan D Curti, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Laboratory tests, vital sign measurements, physical exams and patient interviews will be performed to detect new abnormalities and deteriorations of any pre-existing conditions", 
                "measure": "Assess safety and tolerability according to the National Cancer Institute CTCAE v4.0 (Phase 1 and 2)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 16 weeks"
            }, 
            {
                "description": "Tumor Response by irRC is defined as irPR or irCR over a period of at least 4 weeks", 
                "measure": "Assess Tumor Response by the Immune-related Response Criteria (Phase 2)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12 & week 16"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The serum concentration of Anti-OX40 (CD134) will be determined from its binding to OX40 as measured by ELISA", 
                "measure": "Determine Anti-OX40 serum concentrations", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, on days 1, 3 & 5 30 minutes after Anti-OX40 end of infusion, and on days 8 and 15"
            }, 
            {
                "description": "The biological activity of anti-OX40 in combination with ipilimumab will be assessed by:\nDetermining immunologic changes in the tumor microenvironment by characterization of tumor-infiltrating lymphocytes (TILs), assessment of antigen-specific T cell responses and immunohistochemical (IHC) characterization of tumor and peri-tumoral tissue\nCharacterizing circulating T-cell subsets by flow cytometry\nAssessing antigen specific immune responses by ELISA\nCharacterizing surface markers on lymphocytes and peripheral blood cells by flow cytometry\nMeasuring serum level of soluble factors (cytokine profiling)\nmRNA/miRNA profiling to analyse gene transcription and/or miRNA expression", 
                "measure": "Assess the biological activity of anti-OX40 in combination with ipilimumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day1, day 3, day 5 day8, day 15, day 22 day 43, day 64, day 85 & 113"
            }
        ], 
        "source": "Ludwig Institute for Cancer Research", 
        "sponsors": {
            "collaborator": {
                "agency": "AgonOx", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Ludwig Institute for Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}